Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9199136 | 0.84 | TDP1 (0.39) | TDP1ALDH1A1TSHRCA2GABRA1 | |
| SCHEMBL23621461 | 0.79 | TDP1 (0.41) | TDP1ALDH1A1TSHRCA2GABRA1 | |
| SCHEMBL26002442 | 0.79 | TDP1 (0.41) | TDP1ALDH1A1TSHRCA2GABRA1 | |
| SCHEMBL5148860 | 0.77 | ALDH1A1 (0.43) | TDP1ALDH1A1TSHRCA2GABRA1 | |
| SCHEMBL28680049 | 0.75 | POLB (0.34) | TDP1ALDH1A1TSHR | |
| Chloromethane SCHEMBL27870447 | 0.75 | ESR1 (0.39) | TDP1ALDH1A1TSHR | |
| SCHEMBL6252842 | 0.73 | ALDH1A1 (0.36) | TDP1ALDH1A1TSHRCA2 | |
| SCHEMBL28003547 | 0.72 | ACHE (0.39) | TDP1ALDH1A1TSHRCA2 | |
| SCHEMBL3058322 | 0.72 | TDP1 (0.35) | TDP1ALDH1A1TSHRCA2NPSR1 | |
| SCHEMBL25490766 | 0.72 | TSHR (0.39) | TDP1ALDH1A1TSHRCA2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| WO-2009115893-A2 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO RESEARCH FOUNDATION (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | ENTPD5, PNP, ENTPD1 | TDP1 257/4885ALDH1A1 2855/4885TSHR 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.